These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 27828870)

  • 21. Relation of Neutrophil to Lymphocyte Ratio With Periprocedural Myocardial Damage in Patients Undergoing Elective Percutaneous Coronary Intervention.
    Bressi E; Mangiacapra F; Ricottini E; Cavallari I; Colaiori I; Di Gioia G; Creta A; Di Sciascio G
    Am J Cardiol; 2016 Oct; 118(7):980-4. PubMed ID: 27515894
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased cystatin C levels as a risk factor of cardiovascular events in patients with preserved estimated glomerular filtration rate after elective percutaneous coronary intervention with drug-eluting stents.
    Sai E; Shimada K; Miyauchi K; Masaki Y; Kojima T; Miyazaki T; Kurata T; Ogita M; Tsuboi S; Yoshihara T; Miyazaki T; Ohsaka A; Daida H
    Heart Vessels; 2016 May; 31(5):694-701. PubMed ID: 25863806
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of chronic kidney disease on long-term clinical outcomes after percutaneous coronary intervention with drug-eluting or bare-metal stents.
    Kersting S; Grumann T; Hummel J; Hauschke D; Bode C; Hehrlein C
    Crit Pathw Cardiol; 2012 Sep; 11(3):152-9. PubMed ID: 22825536
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictive Value of Aortic Valve Calcification for Periprocedural Myocardial Injury in Patients Undergoing Percutaneous Coronary Intervention.
    Shibata Y; Ishii H; Suzuki S; Tanaka A; Tatami Y; Harata S; Ota T; Shimbo Y; Takayama Y; Kunimura A; Hirayama K; Harada K; Osugi N; Murohara T
    J Atheroscler Thromb; 2017 May; 24(5):487-494. PubMed ID: 27733732
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association between changes in platelet reactivity during elective percutaneous coronary intervention and periprocedural myocardial infarction: A pilot study.
    Kawai Y; Miyoshi T; Nakamura K; Shokoku G; Yamamoto K; Ono T; Tokioka K; Ohe T; Ito H
    J Cardiol; 2019 Feb; 73(2):134-141. PubMed ID: 30201315
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Periprocedural use of tirofiban in elective percutaneous coronary intervention for long coronary lesions in stable patients with overlapping drug-eluting stents--the PETITION study: a prospective, randomized, multicenter study.
    Zhang Q; Wang XL; Liao ML; Hu J; Yang ZK; Ding FH; Zhang JS; Du R; Zhu TQ; Shen WF; Zhang RY
    Catheter Cardiovasc Interv; 2015 Mar; 85 Suppl 1():762-9. PubMed ID: 25630513
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship Between Preoperative Low-Density Lipoprotein Cholesterol and Periprocedural Myocardial Injury in Patients Following Elective Percutaneous Coronary Intervention in Southern China.
    Zhong Z; Liu J; Zhang Q; Zhong W; Li B; Li C; Liu Z; Yang M; Zhao P
    Med Sci Monit; 2018 Jun; 24():4154-4161. PubMed ID: 29910459
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Short and long term outcome of percutaneous coronary intervention with drug eluting stent and bare metal stent in patients with chronic kidney disease.
    Resmini C; Di Cuia M; Ballocca F; D'Ascenzo F; Bollati M; Moretti C; Omedè PL; Sciuto F; Gaita F; Sheiban I
    Minerva Cardioangiol; 2012 Dec; 60(6):573-80. PubMed ID: 23147435
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term benefits and risks of drug-eluting compared to bare-metal stents in patients with versus without chronic kidney disease.
    Wanitschek M; Pfisterer M; Hvelplund A; De Servi S; Bertel O; Jeger R; Rickenbacher P; Iversen A; Jensen JS; Galatius S; Kaiser C; Alber H;
    Int J Cardiol; 2013 Oct; 168(3):2381-8. PubMed ID: 23453439
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of high-density lipoprotein 3 cholesterol subfraction on periprocedural myocardial injury in patients who underwent elective percutaneous coronary intervention.
    Harada K; Kikuchi R; Suzuki S; Tanaka A; Aoki T; Iwakawa N; Kojima H; Hirayama K; Mitsuda T; Sumi T; Negishi Y; Ishii H; Murohara T
    Lipids Health Dis; 2018 Feb; 17(1):21. PubMed ID: 29391013
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Painless myocardial ischemia is associated with mortality in patients with chronic kidney disease.
    Wetmore JB; Broce M; Malas A; Almehmi A
    Nephron Clin Pract; 2012; 122(1-2):9-16. PubMed ID: 23466572
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of Intravascular Ultrasound- and Optical Coherence Tomography-Assessed Coronary Plaque Morphology With Periprocedural Myocardial Injury in Patients With Stable Angina Pectoris.
    Kimura S; Sugiyama T; Hishikari K; Yamakami Y; Sagawa Y; Kojima K; Ohtani H; Hikita H; Takahashi A; Isobe M
    Circ J; 2015; 79(9):1944-53. PubMed ID: 26095152
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elevated serum miR-133a predicts patients at risk of periprocedural myocardial injury after elective percutaneous coronary intervention.
    Zhou Y; Chen Z; Chen A; Ma J; Qian J; Ge J
    Cardiol J; 2022; 29(2):284-292. PubMed ID: 32207842
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of two-day atorvastatin pretreatment on the incidence of periprocedural myocardial infarction following elective percutaneous coronary intervention: a single-center, prospective, and randomized study.
    Veselka J; Zemánek D; Hájek P; Malý M; Adlová R; Martinkovicová L; Tesar D
    Am J Cardiol; 2009 Sep; 104(5):630-3. PubMed ID: 19699335
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Determinants and Prognostic Significance of Periprocedural Myocardial Injury in Patients With Successful Percutaneous Chronic Total Occlusion Interventions.
    Lee SW; Lee PH; Kang SH; Choi H; Chang M; Roh JH; Yoon SH; Ahn JM; Park DW; Kang SJ; Kim YH; Lee CW; Park SW; Park SJ
    JACC Cardiovasc Interv; 2016 Nov; 9(21):2220-2228. PubMed ID: 27832848
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative Efficacy of Coronary Revascularization Procedures for Multivessel Coronary Artery Disease in Patients With Chronic Kidney Disease.
    Roberts JK; Rao SV; Shaw LK; Gallup DS; Marroquin OC; Patel UD
    Am J Cardiol; 2017 May; 119(9):1344-1351. PubMed ID: 28318510
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of coronary plaque characteristics on periprocedural myocardial injury in elective percutaneous coronary intervention.
    Usami K; Watabe H; Hoshi T; Sakai S; Hiraya D; Sato A; Ieda M
    Eur Radiol; 2023 May; 33(5):3020-3028. PubMed ID: 36441216
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protective effect of nicorandil on myocardial injury following percutaneous coronary intervention in older patients with stable coronary artery disease: Secondary analysis of a randomized, controlled trial (RINC).
    Kawakita N; Ejiri K; Miyoshi T; Kohno K; Nakahama M; Doi M; Munemasa M; Murakami M; Nakamura K; Ito H;
    PLoS One; 2018; 13(4):e0194623. PubMed ID: 29659585
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcomes with prolonged clopidogrel therapy after coronary stenting in patients with chronic kidney disease.
    Siddiqi OK; Smoot KJ; Dufour AB; Cho K; Young M; Gagnon DR; Ly S; Temiyasathit S; Faxon DP; Gaziano JM; Kinlay S
    Heart; 2015 Oct; 101(19):1569-76. PubMed ID: 26209334
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Five-year mortality outcomes in patients with chronic kidney disease undergoing percutaneous coronary intervention.
    Patel AD; Ibrahim M; Swaminathan RV; Minhas IU; Kim LK; Venkatesh P; Feldman DN; Minutello RM; Bergman GW; Wong SC; Singh HS
    Catheter Cardiovasc Interv; 2017 Mar; 89(4):E124-E132. PubMed ID: 27519355
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.